低剂量脱敏疗法不能降低柳氮磺胺吡啶在类风湿关节炎中的毒性。
Low dose desensitisation does not reduce the toxicity of sulphasalazine in rheumatoid arthritis.
作者信息
McInnes I B, Porter D, Murphy E A, Thomson E A, Madhok R, Hunter J A, Pullar T, Capell H A
机构信息
Centre for Rheumatic Diseases, Glasgow Royal Infirmary, United Kingdom.
出版信息
Ann Rheum Dis. 1996 May;55(5):328-30. doi: 10.1136/ard.55.5.328.
OBJECTIVE
To examine the proposal that pretreatment low dose desensitisation may reduce the incidence of toxicity of sulphasalazine in the treatment of rheumatoid arthritis (RA).
METHODS
A double blind, placebo controlled trial was performed with 422 patients satisfying the American College of Rheumatology criteria for RA who required sulphasalazine treatment because of increased disease activity. Patients received either sulphasalazine desensitisation, or placebo, for three weeks before commencement of sulphasalazine treatment. The frequency and nature of adverse effects and changes in clinical and laboratory parameters of disease activity were measured after three and six months.
RESULTS
Improvement in the efficacy of sulphalasazine (measured by clinical and laboratory parameters) was significant and similar in magnitude in both groups. There was no significant difference between actively and placebo desensitised patients as regards the incidence or profile of adverse effects (toxicity).
CONCLUSION
Pretreatment low dose desensitisation is unhelpful in reducing the toxicity associated with sulphasalazine treatment of RA.
目的
检验关于类风湿关节炎（RA）治疗中，预处理低剂量脱敏可降低柳氮磺胺吡啶毒性发生率的提议。
方法
对422例符合美国风湿病学会RA标准且因疾病活动度增加而需接受柳氮磺胺吡啶治疗的患者进行了一项双盲、安慰剂对照试验。在开始柳氮磺胺吡啶治疗前，患者接受柳氮磺胺吡啶脱敏治疗或安慰剂治疗，为期三周。在治疗三个月和六个月后，测量不良反应的频率和性质以及疾病活动度的临床和实验室参数变化。
结果
两组中柳氮磺胺吡啶的疗效改善（通过临床和实验室参数衡量）均显著且幅度相似。在不良反应（毒性）的发生率或情况方面，积极脱敏组和安慰剂脱敏组患者之间无显著差异。
结论
预处理低剂量脱敏无助于降低与柳氮磺胺吡啶治疗RA相关的毒性。
Zotero 插件